Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Nov 27;16:1728721. doi: 10.3389/fphar.2025.1728721

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2025 Ren, Chen, Liu, Wang, Xu, Yang and Qiu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Violin plots depicting data across eight panels labeled A to H. Each panel shows muscle assessment results at Baseline, 1, 3, 6, and 12 months. Colors range from red to blue, indicating time progression. Panels represent MG-ADL, QMG, MGC, and various muscles: Bulbar, Limb, Neck, Respiratory, and Ocular. Annotations indicate statistical significance, with asterisks denoting varying levels. — (A–C) MG-ADL, QMG, and MGC scores before treatment and at 1, 3, 6, and 12 months following ofatumumab treatment in 14 gMG patients. (D–H) QMG scale individual muscle scores for bulbar muscles, limb muscles, neck muscles, respiratory muscles, and ocular muscles before treatment and at 1, 3, 6, and 12 months after ofatumumab treatment in 14 gMG patients. *P < 0.05; **P < 0.01; ***P < 0.001.